In this Korean cohort, SGLT-2 inhibitors were associated with a 16.9% prevalence of erythrocytosis and a 13.1% incidence in patients without baseline erythrocytosis, with male sex, obesity, and smoking as key risk factors. Here, SLC5A2 is linked to polycythemia.